Identification of a conserved linear epitope on the VP1 protein of serotype O foot-and-mouth disease virus by neutralising monoclonal antibody 8E8

Virus Research

Volumn 155, Issue 1, 2011, Pages 291-299

  Yang, Decheng ^a   Zhang, Chunyuan ^a   Zhao, Lei ^a   Zhou, Guohui ^a   Wang, Haiwei ^a   Yu, Li ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Epitope; Foot and mouth disease virus; Monoclonal antibody; Phage display

Indexed keywords

ALANINE; EPITOPE; NEUTRALISING MONOCLONAL ANTIBODY 8E8; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PROTEIN VP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SCREENING; ARTICLE; B LYMPHOCYTE; CHINA; CONTROLLED STUDY; EPITOPE MAPPING; EXPERIMENTAL PIG; FOOT AND MOUTH DISEASE VIRUS; IN VITRO STUDY; IN VIVO STUDY; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MOTIF; SEQUENCE ALIGNMENT; SEROTYPE; VIROPHAGE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CAPSID PROTEINS; CELL LINE; CHINA; CRICETINAE; EPITOPES, B-LYMPHOCYTE; FEMALE; FOOT-AND-MOUTH DISEASE VIRUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDE LIBRARY; SEQUENCE ANALYSIS, DNA; SWINE;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; SUIDAE;

EID: 78650561383     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.10.024     Document Type: Article

References (57)

1. Bachrach H.L. Foot-and-mouth disease. Annu. Rev. Microbiol. 1968, 22:201-244.
2. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., Brown F. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982, 298:30-33.
3. Black L., Francis M.J., Rweyemamu M.M., Umebara O., Boge A. The relationship between serum antibody titres and protection from foot and mouth disease in pigs after oil emulsion vaccination. J. Biol. Stand. 1984, 12:379-389.
4. Boss C.N., Grunebach F., Brauer K., Hantschel M., Mirakaj V., Weinschenk T., Stevanovic S., Rammensee H.G., Brossart P. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin. Cancer Res. 2007, 13:3347-3355.
5. Brown F. New approaches to vaccination against foot-and-mouth disease. Vaccine 1992, 10:1022-1026.
6. Brown F., Cartwright B. Purification of radioactive foot-and-mouth disease virus. Nature 1963, 199:1168-1170.
7. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14943-14948.
8. Chen X., Scala G., Quinto I., Liu W., Chun T.W., Justement J.S., Cohen O.J., vanCott T.C., Iwanicki M., Lewis M.G., Greenhouse J., Barry T., Venzon D., Fauci A.S. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat. Med. 2001, 7:1225-1231.
9. Cheung A., DeLamarter J., Weiss S., Kupper H. Comparison of the major antigenic determinants of different serotypes of foot-and-mouth disease virus. J. Virol. 1983, 48:451-459.
10. Cowan K.M. Antibody response to viral antigens. Adv. Immunol. 1973, 17:195-253.
11. Crowther J.R., Farias S., Carpenter W.C., Samuel A.R. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J. Gen. Virol. 1993, 74(Pt 8):1547-1553.
12. Cunha R.G. Comparison of serum protection tests in guinea-pigs and mice for foot-and-mouth disease antibody evaluation. Can. J. Comp. Med. Vet. Sci. 1963, 27:42-44.
13. DiMarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 1986, 232:639-641.
14. Doel T.R., Gale C., Do Amaral C.M., Mulcahy G., Dimarchi R. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J. Virol. 1990, 64:2260-2264.
15. Domingo E., Biebricher C., Eigen M., Holland J.J. Quasispecies and RNA Virus Evolution: Principles and Consequences 2001, Landes Bioscience, Austin.
16. Domingo E., Escarmis C., Baranowski E., Ruiz-Jarabo C.M., Carrillo E., Nunez J.I., Sobrino F. Evolution of foot-and-mouth disease virus. Virus Res. 2003, 91:47-63.
17. Domingo E., Verdaguer N., Ochoa W.F., Ruiz-Jarabo C.M., Sevilla N., Baranowski E., Mateu M.G., Fita I. Biochemical and structural studies with neutralizing antibodies raised against foot-and-mouth disease virus. Virus Res. 1999, 62:169-175.
18. Fox G., Parry N.R., Barnett P.V., McGinn B., Rowlands D.J., Brown F. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J. Gen. Virol. 1989, 70(Pt 3):625-637.
19. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17:465-493.
20. Haresnape J.M., McCahon D. Four independent antigenic determinants on the capsid polypeptides of aphthovirus. J. Gen. Virol. 1983, 64(Pt 11):2345-2355.
21. Huang C.C., Jong M.H., Lin S.Y. Characteristics of foot and mouth disease virus in Taiwan. J. Vet. Med. Sci. 2000, 62:677-679.
22. Khurana S., Needham J., Mathieson B., Rodriguez-Chavez I.R., Catanzaro A.T., Bailer R.T., Kim J., Polonis V., Cooper D.A., Guerin J., Peterson M.L., Gurwith M., Nguyen N., Graham B.S., Golding H. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J. Virol. 2006, 80:2092-2099.
23. Kitson J.D., McCahon D., Belsham G.J. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 1990, 179:26-34.
24. Knowles N.J., Samuel A.R., Davies P.R., Kitching R.P., Donaldson A.I. Outbreak of foot-and-mouth disease virus serotype O in the UK caused by a pandemic strain. Vet. Rec. 2001, 148:258-259.
25. Knowles N.J., Samuel A.R., Davies P.R., Midgley R.J., Valarcher J.F. Pandemic strain of foot-and-mouth disease virus serotype O. Emerg. Infect. Dis. 2005, 11:1887-1893.
26. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
27. Martinez M.A., Hernandez J., Piccone M.E., Palma E.L., Domingo E., Knowles N., Mateu M.G. Two mechanisms of antigenic diversification of foot-and-mouth disease virus. Virology 1991, 184:695-706.
28. Mason P.W., Pacheco J.M., Zhao Q.Z., Knowles N.J. Comparisons of the complete genomes of Asian, African and European isolates of a recent foot-and-mouth disease virus type O pandemic strain (PanAsia). J. Gen. Virol. 2003, 84:1583-1593.
29. Mason P.W., Rieder E., Baxt B. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:1932-1936.
30. Mateu M.G. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res. 1995, 38:1-24.
31. Mateu M.G., Martinez M.A., Capucci L., Andreu D., Giralt E., Sobrino F., Brocchi E., Domingo E. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J. Gen. Virol. 1990, 71(Pt 3):629-637.
32. Mateu M.G., Martinez M.A., Rocha E., Andreu D., Parejo J., Giralt E., Sobrino F., Domingo E. Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:5883-5887.
33. McCahon D., Crowther J.R., Belsham G.J., Kitson J.D., Duchesne M., Have P., Meloen R.H., Morgan D.O., De Simone F. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J. Gen. Virol. 1989, 70(Pt 3):639-645.
34. McCullough K.C., Crowther J.R., Carpenter W.C., Brocchi E., Capucci L., De Simone F., Xie Q., McCahon D. Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology 1987, 157:516-525.
35. McCullough K.C., De Simone F., Brocchi E., Capucci L., Crowther J.R., Kihm U. Protective immune response against foot-and-mouth disease. J. Virol. 1992, 66:1835-1840.
36. Mulcahy G., Pullen L.A., Gale C., DiMarchi R.D., Doel T.R. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine 1991, 9:19-24.
37. Pay T.W., Hingley P.J. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine 1987, 5:60-64.
38. Pay T.W., Hingley P.J. Foot and mouth disease vaccine potency tests in cattle: the interrelationship of antigen dose, serum neutralizing antibody response and protection from challenge. Vaccine 1992, 10:699-706.
39. Pereira H.G. Foot and Mouth Disease 1981, Academic Press Inc., London, United Kingdom.
40. Pfaff E., Mussgay M., Bohm H.O., Schulz G.E., Schaller H. Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. EMBO J. 1982, 1:869-874.
41. Pfaff E., Thiel H.J., Beck E., Strohmaier K., Schaller H. Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol. 1988, 62:2033-2040.
42. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6:404-414.
43. Rowley M.J., O'Connor K., Wijeyewickrema L. Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. Biotechnol. Annu. Rev. 2004, 10:151-188.
44. Rueckert R.R. Picornaviridae: The Viruses and their Replication 1996, Lippincott-Raven, Philadelphia, PA.
45. Samuel A.R., Knowles N.J. Foot-and-mouth disease type O viruses exhibit genetically and geographically distinct evolutionary lineages (topotypes). J. Gen. Virol. 2001, 82:609-621.
46. Sobrino F., Saiz M., Jimenez-Clavero M.A., Nunez J.I., Rosas M.F., Baranowski E., Ley V. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet. Res. 2001, 32:1-30.
47. Steward M.W. The development of a mimotope-based synthetic peptide vaccine against respiratory syncytial virus. Biologicals 2001, 29:215-219.
48. Strohmaier K., Franze R., Adam K.H. Location and characterization of the antigenic portion of the FMDV immunizing protein. J. Gen. Virol. 1982, 59:295-306.
49. Thomas A.A., Woortmeijer R.J., Puijk W., Barteling S.J. Antigenic sites on foot-and-mouth disease virus type A10. J. Virol. 1988, 62:2782-2789.
50. Torresi J., Stock O.M., Fischer A.E., Grollo L., Drummer H., Boo I., Zeng W., Earnest-Silveira L., Jackson D.C. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 2007, 45:911-920.
51. Verdaguer N., Fita I., Domingo E., Mateu M.G. Efficient neutralization of foot-and-mouth disease virus by monovalent antibody binding. J. Virol. 1997, 71:9813-9816.
52. Verdaguer N., Sevilla N., Valero M.L., Stuart D., Brocchi E., Andreu D., Giralt E., Domingo E., Mateu M.G., Fita I. A similar pattern of interaction for different antibodies with a major antigenic site of foot-and-mouth disease virus: implications for intratypic antigenic variation. J. Virol. 1998, 72:739-748.
53. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
54. Wang L.F., Yu M. Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. Curr. Drug Targets 2004, 5:1-15.
55. Weiss G.A., Watanabe C.K., Zhong A., Goddard A., Sidhu S.S. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8950-8954.
56. Xie Q.C., McCahon D., Crowther J.R., Belsham G.J., McCullough K.C. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J. Gen. Virol. 1987, 68(Pt 6):1637-1647.
57. Yang D., Tu Y., Wang H., Zhou G., Yu L. Construction of infectious cDNA clone for PanAsia strain of FMDV serotype O. Chin. J. Prev. Vet. Med. 2009, 31:1-5.